Prevalence and Burden of Breathlessness in Patients with Chronic Obstructive Pulmonary Disease Managed in Primary Care-Reference-Cited by-同舟云学术

Prevalence and Burden of Breathlessness in Patients with Chronic Obstructive Pulmonary Disease Managed in Primary Care

Published:2014-01-10 Issue:1 Volume:9 Page:e85540
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Müllerová Hana,Lu Chao,Li Hao,Tabberer Maggie

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference42 articles.

1. Gold Initiative for Chronic Obstructive Lung Disease. (2011) Global strategy for diagnosis, management, and prevention of COPD. Available: http://www goldcopd org/guidelines-global-strategy-for-diagnosis-management html. Accessed 3^rd December 2012.

2. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease;JC Bestall;Thorax,1999

3. Evaluation of the dyspneic patient in the office;S Sarkar;Prim Care,2006

4. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea;MB Parshall;Am J Respir Crit Care Med,2012

5. A physiological model of patient-reported breathlessness during daily activities in COPD;CJ Jolley;Eur Respir Rev,2009

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Residual reversibility in COPD patients already on long-acting bronchodilator: The OscilloRevers Study;Respiratory Medicine and Research;2024-06

2. Pulmonary Rehabilitation with and without a Cognitive Behavioral Intervention for Breathlessness in People Living with Chronic Obstructive Pulmonary Disease: Randomized Controlled Trial;Journal of Clinical Medicine;2023-11-24

3. Overuse of long-acting β ₂ -agonist/inhaled corticosteroids in patients with chronic obstructive pulmonary disease: time to rethink prescribing patterns;Postgraduate Medicine;2023-11-17

4. Budget impact analysis of adopting primary care–based case detection of chronic obstructive pulmonary disease in the Canadian general population;CMAJ Open;2023-11

5. Improvement of exertional dyspneoa in patients with chronic obstructive pulmonary disease and severe allergic asthma responding to omalizumab;Clinical & Experimental Allergy;2023-09-13